The 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy

The Body Covers:

The 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy

Metro Toronto Convention Centre, Toronto, Ontario, Canada

September 17-20, 2000

Conference Summaries
Reports and Related Articles


		Cal Cohen, M.D.	Edwin DeJesus, M.D.	Alvan Fisher, M.D.


Howard Grossman, M.D.	Mark Holodniy, M.D.	Pablo Tebas, M.D.	Benjamin Young, M.D.

The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), an annual meeting of American Society for Microbiology, is the major international meeting on antimicrobial agents and infectious diseases.

In addition to its scientific symposia, the conference includes special lectures, slide sessions, poster presentations, minilectures, meet-the-experts roundtables, interactive sessions and will this year include an opening session on AIDS. Complementing the invited sessions are an increased number of abstract sessions, which allow for the presentation of new and significant developments in therapy, prevention, pathogenesis, epidemiology, immunology and diagnosis of both established and emerging infectious diseases.

Funding for this conference coverage at The Body is provided, in part, through unrestricted educational grants by Agouron Pharmaceuticals, Inc.; DuPont Pharmaceuticals Company; Glaxo Wellcome Inc.; Merck & Co., Inc.; Ortho Biotech, Inc.; and Roxane Laboratories, Inc.

The Body's Conference Summaries
Day One Sunday, September 17	Day Two Monday, September 18	Day Three Tuesday, September 19	Day Four Wednesday, September 20
Pharmacoeconomics and Epidemiology of Antibiotic Use Meet the Experts Session Drug-Drug Interactions in HIV Infections Potential Role of Protease Inhibitor-Sparing Regimens in Antiretroviral Therapy Clinical Trials of Antiretroviral Therapy New Anti-HIV Agents Pathogenesis of HIV Disease and other Retrovirus Diseases Immunology of HIV Infection	Clinical Trials of Antiretroviral Therapy Adherence to Antiretroviral Therapy Primary HIV Infection Symposium: Viral Co-Infection with HIV New Approaches with Antiretroviral Therapy Analysis of Genotypes Prior to Antiretroviral Therapy Antiretroviral Resistance and Resistance Testing Lipodystrophy and Metabolic Disorders in HIV Therapeutics	Lipodystrophy and Metabolic Complications of HIV Strategies for Switching Antiretroviral Therapy Antiretroviral Drug-Drug Interactions and Adverse Effects Pharmacokinetics and Pharmacodynamics of Antiretroviral Drugs Symposium: New Challenges in Antiretroviral Therapy and Patient Management of HIV Changing Epidemiology of HIV Disease The Impact of HAART on the Outcome of HIV Disease: Challenges for Clinical Trial Design	Novel Aspects of Resistance to Antiretroviral Agents

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.